The results from SELECT will be instrumental in changing the way we perceive and treat obesity. Exploring data on the cardiovascular impact of weekly semaglutide treatments from the SELECT trial SELECT enrolled more than 17,000 patients with pre-existing cardiovascular disease who were overweight or obese, but did not present with diabetes
Furthermore, the literature indicates that aside from their benefits in weight management and glycemic control, GLP-1 RAs have favorable effects on metabolic profiles, including blood pressure and lipid levels 22
Ozempic is the brand name for semaglutide, manufactured by Novo Nordisk
J Med Case Rep
The BNF advises that patients presenting with neurological symptoms should receive 1000 mcg i.m
At Southern Care Anesthetics, our team utilizes BPC-157 to help patients recover faster from both acute and chronic conditions, supporting overall health and well-being